BioSpace News Archive

Zura Bio Limited announced that members of its senior management team will present at two upcoming conferences in January.

Acquisition amplifies Ampersand’s in-house capabilities to generate AND-Body™ Therapeutics - programmed biologics across a broad range of diseases

BioCryst Pharmaceuticals, Inc. announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024, at 6:00 p.m. ET.

Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, is pleased to announce the appointment of Dr. Brian Alvin Johns, Ph.D., as Chief Scientific Officer, effective January 3, 2024.

Atea Pharmaceuticals, Inc. announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 10:30 a.m. PT in San Francisco, CA.

Voyager Therapeutics, Inc. announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2024, at 9:45 a.m. PT.

Asensus Surgical, Inc. announced that the management team will participate and present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 3:00pm EST.

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces it has sold and shipped over one million Canadian Dollars of its quality assessment products to a leading agency that provides clinical laboratory accreditation services.

Tango Therapeutics, Inc. announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG348 as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant or other HRD+ cancers.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced it has submitted a New Drug Application to the U.S. Food and Drug Administration for govorestat for the treatment of Classic Galactosemia.